Morgan Stanley (NYSE:MS) analyst Nigel Dally maintained a Sell rating on Globe Life (NYSE:GL) Inc. on Thursday, setting a price target of $100, which is approximately 3.49% above the present share price of $96.63.
Dally expects Globe Life Inc. to post earnings per share (EPS) of $1.96 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Hold rating of shares in Globe Life, with an average price target of $93.67.
The analysts price targets range from a high of $95 to a low of $91.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.23 billion and a net profit of $0. The company's market cap is $11.2 billion.
According to TipRanks.com, Morgan Stanley analyst Nigel Dally is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 18.3% and a 63.41% success rate.
Globe Life, Inc. is a holding company, which engages in the provision of individual life and supplemental health insurance products and services. It operates through the following segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. The Life Insurance segment includes traditional and interest-sensitive whole life insurance as well as term life insurances. The Supplement Health Insurance segment provides generally guaranteed-renewable and include medicare supplement, critical illness, accident, and limited-benefit supplemental hospital, and surgical coverage. The Annuities segment refers to fixed-benefit contracts. The Investments segment covers the investment portfolio. The company was founded on November 19, 1979 and is headquartered in McKinney, TX.